Close
Help




JOURNAL

Clinical Medicine Insights: Oncology

Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies

Submit a Paper


Clinical Medicine Insights: Oncology 2016:10 43-48

Review

Published on 12 May 2016

DOI: 10.4137/CMO.S32821


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology

Abstract

Cholangiocarcinoma is a very heterogeneous and rare group of neoplasms originating from the perihilar, intra-, or extrahepatic bile duct epithelium. It represents only 3% of gastrointestinal cancers, although their incidence is increasing as its mortality increases. Surgical resection is the only potentially curative option, but unfortunately the resectability rate is low. Overall, these malignancies have got a very poor prognosis with a five-year survival rate of 5–10%. Although the five-year survival rate increases to 25–30% in the cases amenable to surgery, only 10–40% of patients present with resectable disease. Therefore, it is necessary to optimize the benefit of adjuvant strategies after surgery to increase the rate of curability. This study reviewed the role of adjuvant chemotherapy in resectable bile duct cancers.



Downloads

PDF  (388.12 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




Quick Links


New article and journal news notification services